The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase. (Q27824815)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase. |
scientific article |
Statements
2 references
The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase (English)
Tetsuya Kurosu
Kazuhiko Kakihana
Daisuke Mizuchi
Identifiers
2 references
2 references